Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna

Breakthrough cancer vaccine could be ready in months, say scientists

Manufacturers Moderna and Merck are testing a breakthrough cancer vaccine for patients suffering from melanoma which kills thousands of people each year in the UK

Daily Mirror

Bear Market Hits New Lows, But Stocks Rebound After Hot CPI Inflation Report: Weekly Review

The major indexes tumbled to bear market lows after a hot CPI inflation report, but then roared back. Earnings season is getting underway.

Investors Business Daily

How Western countries could stop Africa making vaccines of the future

While Western donors have stumped up significant funding for a programme to make Covid-19 vaccines in Africa, activists say more support is needed to help poor countries secure the intellectual property rights they need to produce mRNA vaccines beyond the pandemic.

Radio France Internationale

From analysis to the latest developments in health,
read the most diverse news in one place.

Fla. surgeon general's anti-vax warning

"This study is too flawed to be used to set policy on the mRNA vaccines in younger males," one expert said

Salon

Check Out What Whales Are Doing With MRNA

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 26 strange trades.

Benzinga

Why Norwegian Cruise Line Shares Climbed By Around 12%; Here Are 66 Biggest Movers From Yesterday

Gainers Pintec Technology Holdings Limited (NASDAQ: PT) shares jumped 216.2% to close at $0.9058 on Wednesday.

Benzinga

Moderna Rallies On Merck Collaboration: Can Drugmaker Replace COVID Vaccine Revenue?

In late 2020, when the world was searching for a vaccine or cure for COVID-19, the price action in Moderna Inc (NASDAQ: MRNA) was discussed frequently on Benzinga's PreMarket Prep show.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

FDA authorizes COVID omicron boosters for kids 5 and up

COVID-19 vaccine makers Pfizer Inc. and Moderna Inc. received U.S. regulatory clearances for their omicron-targeted boosters for children as young as 5.

Tribune News Service

Why T2 Biosystems Shares Are Trading Lower By Over 28%, Here Are 41 Stocks Moving In Wednesday's Mid-Day Session

Gainers Code Chain New Continent Limited (NYSE: CCNC) shares jumped 74% to $0.2868 after declining around 14% on Tuesday.

Benzinga

Stock Market Inching Higher; Fed Minutes On Tap; Education Stock Breaks Out

The stock market flashed a mild shade of green at noon on Wednesday. Investors now await the 2pm Fed Minutes.

Investors Business Daily

Omicron boosters for kids 5-12 are cleared by the CDC

Tweaked boosters rolled out for Americans 12 and older last month, modified to target today's most common and contagious variant. The latest move may expand protection before an expected winter wave.

WEKU

FDA clears updated COVID boosters for kids as young as 5

The U.S. is about to offer updated COVID-19 booster shots to kids as young as 5

The Independent UK

Moderna Surges As Merck Inks Deal To Co-Develop Personalized Cancer Vaccine Treatment

Merck opted Wednesday to help Moderna develop a personalized cancer vaccine based on messenger RNA technology, and MRNA stock rocketed.

Investors Business Daily

10 Fallen Growth Stocks Will Make You Up To 113% Richer, Analysts Say

Seeing S&P 500 growth stocks implode is tough to watch, unless you're ready to spot a buy point.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Radio France Internationale

Africa overcomes the odds to produce its own Covid vaccines

Set on redressing vaccine inequality between rich and poor nations, a South African consortium is taking on pharmaceutical giants in its quest to produce Africa's first homegrown mRNA Covid-19 vaccine and share it with the global south.

ABC News

Australian adults can now get Moderna's Omicron COVID-19 booster. Here's what we know

How can we get the new two-in-one COVID booster, what's in it, and how much protection does it provide?

Benzinga

Looking At Moderna's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

The Guardian - UK

‘Like copying a Louis Vuitton handbag’: big pharma hits out at Africa’s replica Covid vaccine

Knowledge-sharing hub in Cape Town reverse engineered the Moderna vaccine, but future of the initiative to reduce inequity remains unsure

Get all your
news in one place.

100’s of premium titles.
One news app.

Daily Record

The new Covid wave - what you should know from symptoms to facemasks and flu risk

Covid cases have been increasing ahead of the winter flu season.

Benzinga

Check Out What Whales Are Doing With MRNA

Benzinga

This Is What Whales Are Betting On Moderna

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 25 strange trades.

Benzinga

Bloomberg

Salon

No, AI won't change Big Pharma

Claims that artificial intelligence will change the way drugs are made are almost certainly overblown. Here’s why

Axios

Moderna seeks emergency authorization for COVID booster for children

The application for children ages 6 months to under 6 years is expected to be completed later this year.

Los Angeles Times

Moderna vs. Pfizer: Is it OK to mix and match the updated COVID-19 booster shots?

LOS ANGELES — As residents prepare to roll up their sleeves for a third, fourth or even fifth dose of COVID-19 vaccine, some may be wondering: Do I need to stick with the same brand, or is it safe to mix it up?

1 … 15 16 17 18

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Intellectual Property

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.